{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-279962","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2021-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.300706+00:00","generated_at":"2026-06-29T01:49:11.839980+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Solid Biosciences reports SGT-001 1.5-year data showing functional benefit in DMD patients 4-6","bullets":["NSAA mean decrease 1.7 pts vs expected 4.5 pt decline from natural history; difference +2.8 pts.","6MWT mean increase 15.3 meters vs expected 63.5-meter decline; difference +78.8 meters.","Percent predicted FVC improved 4.1% vs expected 7.5% decline; difference +11.6%.","PODCI global, sports, transfer, upper-body scales showed sustained improvements at 1.5 years.","No new drug-related safety findings in patients with post-dosing periods up to 3.5 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-279962","json":"https://secwatch.observer/filing/0001193125-21-279962.json","markdown":"https://secwatch.observer/filing/0001193125-21-279962.md","text":"https://secwatch.observer/filing/0001193125-21-279962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521279962/0001193125-21-279962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521279962/d200279d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:49:11.839980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}